Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Investors

Shield Therapeutics is well positioned to become a fast growing, independent, international specialty pharmaceutical company.

video

Tim Watts, CEO, Shield Therapeutics presentation at the Shares Investor Event, 3 June

Jun 2020 - 24:40
audio

Shield Therapeutics, Blencowe Resources and John Mayor on the Markets & Commodities

May 2020 - 42:54

Reasons to invest in Shield.

Large markets of patients poorly treated for iron deficiency

Large markets of patients poorly treated for iron deficiency

2 billion
WHO estimates of global prevalence of Iron Deficiency

Feraccru© approved and launched in Europe

Feraccru© approved and launched in Europe

Partnered with Norgine in Europe, Australia and New Zealand
40 million ID sufferers in Europe

Licensed to ASK Pharm in China

Licensed to ASK Pharm in China

Population of 1.4 billion people

Accrufer© approved in USA

Accrufer© approved in USA

Partnering process underway
10 million IDA patients in USA

Feracru©/Accrufer© patants extend to

Feracru©/Accrufer© patants extend to

2035

Novel phosphate binder in pipeline

Novel phosphate binder in pipeline

Current cash runway extends to

Current cash runway extends to

Q1-2021